Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Two Bear Capital
Deal Size : $11.2 million
Deal Type : Financing
Talus Bio Tacks on $11M to Target Hard-To-Reach Transcription Factors
Details : The funding will be invested to advance Talus Bio’s therapeutic programs, which include Brachyury-driven cancers and an undruggable transcription factor implicated in prostate cancer.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 20, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Two Bear Capital
Deal Size : $11.2 million
Deal Type : Financing